Real-time enrollment status for this transthyretin-mediated amyloidosis clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 8:48 AM UTC
| NCT Number | NCT04561518 |
| Recruiting Status | Recruiting |
| Condition | Transthyretin-Mediated Amyloidosis |
| Phase | Clinical Trial |
| Target Enrollment | 1,500 participants |
| Active Locations | 13 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | May 29, 2026 (May 29, 2026) |
As of July 13, 2026: Clinical trial NCT04561518 is currently recruiting participants. This clinical trial study for transthyretin-mediated amyloidosis is actively seeking new participants at 13 locations across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT04561518 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 13 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT04561518 was last updated May 29, 2026 (May 29, 2026). HelloStudys verifies this status automatically.